Jacob Trotta
About Jacob Trotta
Jacob Trotta is a Senior Scientist at Alkermes with expertise in the analytical development of proteins, polymorphs, and polymers.
Current Title and Role
Jacob Trotta is currently a Senior Scientist at Alkermes. His role involves working on the analytical development of proteins, polymorphs, and polymers. He specializes in developing analytical methods for complex pharmaceutical formulations, contributing significantly to the company's R&D initiatives.
Previous Positions and Experience
Jacob Trotta has extensive experience in both academic and industrial research environments. Before his current position, he worked as a Scientist at Alkermes from 2019 to 2021. He served as a Graduate Research Assistant at Fors Research Group, Cornell University from 2014 to 2019. Additionally, he was a Research Assistant at Villanova University Department of Chemistry in 2014, and earlier, he interned at Alkermes, Inc from 2011 to 2014.
Education and Academic Credentials
Jacob Trotta holds a Doctor of Philosophy (PhD) degree in Polymer Chemistry from Cornell University, attained after five years of study from 2014 to 2019. He also obtained a Bachelor's Degree in Chemistry from Villanova University, where he studied from 2010 to 2014. Trotta completed his high school education at Concord-Carlisle Regional High School, graduating in 2010.
Specialization and Expertise
Jacob Trotta specializes in the analytical development of proteins, polymorphs, and polymers. His expertise includes automation within the field of analytical development. His work primarily focuses on creating and refining analytical methods to support the development of complex pharmaceutical formulations.
Research and Development Contributions
During his doctoral studies at Cornell University, Jacob Trotta conducted research projects focused on polymer chemistry. In his current and previous roles at Alkermes, he has contributed to the development of analytical methods for complex pharmaceutical formulations, ensuring the reliability and efficiency of new drug development processes.